BusinessHorizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye DiseaseBy Nasdaq OMXOct 25, 2017, 12:01 PM UTC
